These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38740087)

  • 21. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.
    Fernández-Tussy P; Cardelo MP; Zhang H; Sun J; Price NL; Boutagy NE; Goedeke L; Cadena-Sandoval M; Xirouchaki CE; Brown W; Yang X; Pastor-Rojo O; Haeusler RA; Bennett AM; Tiganis T; Suárez Y; Fernández-Hernando C
    JCI Insight; 2024 Aug; 9(19):. PubMed ID: 39190492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver.
    Guinez C; Filhoulaud G; Rayah-Benhamed F; Marmier S; Dubuquoy C; Dentin R; Moldes M; Burnol AF; Yang X; Lefebvre T; Girard J; Postic C
    Diabetes; 2011 May; 60(5):1399-413. PubMed ID: 21471514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice.
    Bricambert J; Miranda J; Benhamed F; Girard J; Postic C; Dentin R
    J Clin Invest; 2010 Dec; 120(12):4316-31. PubMed ID: 21084751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocyte-specific loss of DDB1 attenuates hepatic steatosis but aggravates liver inflammation and fibrosis in MASH.
    Gu Q; Chang Y; Jin Y; Fang J; Ji T; Lin J; Zhu X; Dong B; Ying H; Fan X; Li Z; Gao Z; Zhu Y; Tong Y; Cai X
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38934719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells.
    Che L; Stevenson CK; Plas DR; Wang J; Du C
    bioRxiv; 2024 Sep; ():. PubMed ID: 39314445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity.
    Zhang D; Tong X; VanDommelen K; Gupta N; Stamper K; Brady GF; Meng Z; Lin J; Rui L; Omary MB; Yin L
    J Clin Invest; 2017 Jun; 127(7):2855-2867. PubMed ID: 28628040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FNDC5 Alleviates Hepatosteatosis by Restoring AMPK/mTOR-Mediated Autophagy, Fatty Acid Oxidation, and Lipogenesis in Mice.
    Liu TY; Xiong XQ; Ren XS; Zhao MX; Shi CX; Wang JJ; Zhou YB; Zhang F; Han Y; Gao XY; Chen Q; Li YH; Kang YM; Zhu GQ
    Diabetes; 2016 Nov; 65(11):3262-3275. PubMed ID: 27504012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic Aryl Hydrocarbon Receptor Attenuates Fibroblast Growth Factor 21 Expression.
    Girer NG; Murray IA; Omiecinski CJ; Perdew GH
    J Biol Chem; 2016 Jul; 291(29):15378-87. PubMed ID: 27226639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinol saturase coordinates liver metabolism by regulating ChREBP activity.
    Heidenreich S; Witte N; Weber P; Goehring I; Tolkachov A; von Loeffelholz C; Döcke S; Bauer M; Stockmann M; Pfeiffer AFH; Birkenfeld AL; Pietzke M; Kempa S; Muenzner M; Schupp M
    Nat Commun; 2017 Aug; 8(1):384. PubMed ID: 28855500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terf2ip deficiency accelerates non-alcoholic steatohepatitis through regulating lipophagy and fatty acid oxidation via Sirt1/AMPK pathway.
    Wang Y; Liu S; Ni M; Chen Y; Chen R; Wang J; Jiang W; Zhou T; Fan S; Chang J; Xu X; Zhang Y; Yu Y; Li X; Li C
    Free Radic Biol Med; 2024 Aug; 220():78-91. PubMed ID: 38697492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP.
    Mendoza A; Tang C; Choi J; Acuña M; Logan M; Martin AG; Al-Sowaimel L; Desai BN; Tenen DE; Jacobs C; Lyubetskaya A; Fu Y; Liu H; Tsai L; Cohen DE; Forrest D; Wilson AA; Hollenberg AN
    Sci Signal; 2021 Nov; 14(709):eabh3839. PubMed ID: 34784250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by glucose, n-3 polyunsaturated fatty acids, and peroxisome proliferator-activated receptor-alpha agonist.
    Xu J; Christian B; Jump DB
    J Biol Chem; 2006 Jul; 281(27):18351-62. PubMed ID: 16644726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes.
    Wang H; Cao Y; Shu L; Zhu Y; Peng Q; Ran L; Wu J; Luo Y; Zuo G; Luo J; Zhou L; Shi Q; Weng Y; Huang A; He TC; Fan J
    J Cell Mol Med; 2020 Jan; 24(2):1399-1412. PubMed ID: 31809000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
    Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
    Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver ChREBP deficiency inhibits fructose-induced insulin resistance in pregnant mice and female offspring.
    Li J; Zhang S; Sun Y; Li J; Feng Z; Li H; Zhang M; Yan T; Han J; Duan Y
    EMBO Rep; 2024 Apr; 25(4):2097-2117. PubMed ID: 38532128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
    Gallego-Durán R; Ampuero J; Maya-Miles D; Pastor-Ramírez H; Montero-Vallejo R; Rivera-Esteban J; Álvarez-Amor L; Pareja MJ; Rico MC; Millán R; Robles-Frías MJ; Aller R; Rojas Á; Muñoz-Hernández R; Gil-Gómez A; Gato S; García-Lozano M; Arias-Loste MT; Abad J; Calleja JL; Andrade RJ; Crespo J; González-Rodríguez Á; García-Monzón C; Andreola F; Pericás JM; Jalan R; Martín-Bermudo F; Romero-Gómez M
    United European Gastroenterol J; 2024 Oct; 12(8):1056-1068. PubMed ID: 38894596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.